JLab Hear OTC vs Otofonix Groove

The JLab Hear OTC is a budget-priced OTC hearing aid released in 2024, earning a B grade with a SoundScore of 3.5/5 in our lab testing. At $100, it represents one of the most affordable entry points into the OTC hearing aid market, ranking #36 of 65 devices in its category. This visible-in-ear device delivers a distinctive performance profile with clear strengths and weaknesses. Its standout feature is excellent music streaming quality, scoring 4.6/5—a remarkable 2.68 points above the category average. Feedback handling is equally impressive at 5.0/5, meaning users can expect stable performance without whistling during daily activities. These results suggest JLab leveraged its audio expertise from consumer earbuds in developing this product. However, speech clarity presents challenges. Speech in quiet scored 2.1/5 (0.67 points below category average), while speech in noise scored 1.0/5 (0.46 points below average). Own-voice comfort also measured low at 1.8/5. These limitations are significant for users prioritizing conversation clarity, which is typically the primary reason people seek hearing aids. The JLab Hear OTC is best suited for budget-conscious consumers who value music and media streaming alongside basic amplification, rather than those needing maximum speech intelligibility. Features include rechargeable batteries, iPhone and Android streaming, and hands-free functionality. Buyers seeking stronger speech performance in this price range may want to compare options like the higher-scoring Elehear Beyond or Apple AirPods Pro 2.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.